254 related articles for article (PubMed ID: 19227011)
1. Noninvasive radiofrequency field-induced hyperthermic cytotoxicity in human cancer cells using cetuximab-targeted gold nanoparticles.
Curley SA; Cherukuri P; Briggs K; Patra CR; Upton M; Dolson E; Mukherjee P
J Exp Ther Oncol; 2008; 7(4):313-26. PubMed ID: 19227011
[TBL] [Abstract][Full Text] [Related]
2. Use of nanoparticles for targeted, noninvasive thermal destruction of malignant cells.
Cherukuri P; Curley SA
Methods Mol Biol; 2010; 624():359-73. PubMed ID: 20217608
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive radiofrequency field destruction of pancreatic adenocarcinoma xenografts treated with targeted gold nanoparticles.
Glazer ES; Zhu C; Massey KL; Thompson CS; Kaluarachchi WD; Hamir AN; Curley SA
Clin Cancer Res; 2010 Dec; 16(23):5712-21. PubMed ID: 21138869
[TBL] [Abstract][Full Text] [Related]
4. Radiofrequency field-induced thermal cytotoxicity in cancer cells treated with fluorescent nanoparticles.
Glazer ES; Curley SA
Cancer; 2010 Jul; 116(13):3285-93. PubMed ID: 20564640
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic carcinoma cells are susceptible to noninvasive radio frequency fields after treatment with targeted gold nanoparticles.
Glazer ES; Massey KL; Zhu C; Curley SA
Surgery; 2010 Aug; 148(2):319-24. PubMed ID: 20541785
[TBL] [Abstract][Full Text] [Related]
6. PEGylated gold nanoparticles conjugated to monoclonal F19 antibodies as targeted labeling agents for human pancreatic carcinoma tissue.
Eck W; Craig G; Sigdel A; Ritter G; Old LJ; Tang L; Brennan MF; Allen PJ; Mason MD
ACS Nano; 2008 Nov; 2(11):2263-72. PubMed ID: 19206392
[TBL] [Abstract][Full Text] [Related]
7. Enhanced cytotoxic activity of cetuximab in EGFR-positive lung cancer by conjugating with gold nanoparticles.
Qian Y; Qiu M; Wu Q; Tian Y; Zhang Y; Gu N; Li S; Xu L; Yin R
Sci Rep; 2014 Dec; 4():7490. PubMed ID: 25502402
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies.
Riemer AB; Kurz H; Klinger M; Scheiner O; Zielinski CC; Jensen-Jarolim E
J Natl Cancer Inst; 2005 Nov; 97(22):1663-70. PubMed ID: 16288119
[TBL] [Abstract][Full Text] [Related]
9. Cetuximab conjugated O-carboxymethyl chitosan nanoparticles for targeting EGFR overexpressing cancer cells.
Maya S; Kumar LG; Sarmento B; Sanoj Rejinold N; Menon D; Nair SV; Jayakumar R
Carbohydr Polym; 2013 Apr; 93(2):661-9. PubMed ID: 23499109
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-2 potentiation of cetuximab antitumor activity for epidermal growth factor receptor-overexpressing gastric cancer xenografts through antibody-dependent cellular cytotoxicity.
Hara M; Nakanishi H; Tsujimura K; Matsui M; Yatabe Y; Manabe T; Tatematsu M
Cancer Sci; 2008 Jul; 99(7):1471-8. PubMed ID: 18422755
[TBL] [Abstract][Full Text] [Related]
11. Designing nanoconjugates to effectively target pancreatic cancer cells in vitro and in vivo.
Khan JA; Kudgus RA; Szabolcs A; Dutta S; Wang E; Cao S; Curran GL; Shah V; Curley S; Mukhopadhyay D; Robertson JD; Bhattacharya R; Mukherjee P
PLoS One; 2011; 6(6):e20347. PubMed ID: 21738572
[TBL] [Abstract][Full Text] [Related]
12. Selective photothermal efficiency of citrate capped gold nanoparticles for destruction of cancer cells.
Raji V; Kumar J; Rejiya CS; Vibin M; Shenoi VN; Abraham A
Exp Cell Res; 2011 Aug; 317(14):2052-8. PubMed ID: 21565190
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab.
Lu Y; Li X; Liang K; Luwor R; Siddik ZH; Mills GB; Mendelsohn J; Fan Z
Cancer Res; 2007 Sep; 67(17):8240-7. PubMed ID: 17804738
[TBL] [Abstract][Full Text] [Related]
14. Targeted delivery and enhanced cytotoxicity of cetuximab-saporin by photochemical internalization in EGFR-positive cancer cells.
Yip WL; Weyergang A; Berg K; Tønnesen HH; Selbo PK
Mol Pharm; 2007; 4(2):241-51. PubMed ID: 17263556
[TBL] [Abstract][Full Text] [Related]
15. Narrow band imaging of squamous cell carcinoma tumors using topically delivered anti-EGFR antibody conjugated gold nanorods.
Puvanakrishnan P; Diagaradjane P; Kazmi SM; Dunn AK; Krishnan S; Tunnell JW
Lasers Surg Med; 2012 Apr; 44(4):310-7. PubMed ID: 22415634
[TBL] [Abstract][Full Text] [Related]
16. Nanoconjugation modulates the trafficking and mechanism of antibody induced receptor endocytosis.
Bhattacharyya S; Bhattacharya R; Curley S; McNiven MA; Mukherjee P
Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14541-6. PubMed ID: 20679244
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of EGFR-targeted radioimmuno-gold-nanoparticles as a theranostic agent in a tumor animal model.
Kao HW; Lin YY; Chen CC; Chi KH; Tien DC; Hsia CC; Lin MH; Wang HE
Bioorg Med Chem Lett; 2013 Jun; 23(11):3180-5. PubMed ID: 23628334
[TBL] [Abstract][Full Text] [Related]
18. Specific cell targeting with nanobody conjugated branched gold nanoparticles for photothermal therapy.
Van de Broek B; Devoogdt N; D'Hollander A; Gijs HL; Jans K; Lagae L; Muyldermans S; Maes G; Borghs G
ACS Nano; 2011 Jun; 5(6):4319-28. PubMed ID: 21609027
[TBL] [Abstract][Full Text] [Related]
19. Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent.
Patra CR; Bhattacharya R; Wang E; Katarya A; Lau JS; Dutta S; Muders M; Wang S; Buhrow SA; Safgren SL; Yaszemski MJ; Reid JM; Ames MM; Mukherjee P; Mukhopadhyay D
Cancer Res; 2008 Mar; 68(6):1970-8. PubMed ID: 18339879
[TBL] [Abstract][Full Text] [Related]
20. Surface plasmon resonance-induced photoactivation of gold nanoparticles as mitochondria-targeted therapeutic agents for pancreatic cancer.
Mocan L; Ilie I; Tabaran FA; Dana B; Zaharie F; Zdrehus C; Puia C; Mocan T; Muntean V; Teodora P; Ofelia M; Marcel T; Iancu C
Expert Opin Ther Targets; 2013 Dec; 17(12):1383-93. PubMed ID: 24188208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
